PD-Rx Pharmaceuticals, Inc. Reports Earnings for 2007
Published: Nov 12, 2007
OKLAHOMA CITY, Nov. 9 /PRNewswire-FirstCall/ -- For the fiscal year ending June 30th, 2007, PD-Rx set record sales of $21.8 million up 51% over last year's sales figures of $14.4 million. Net profits increased by 82% in 2007 to $893,069 up from $491,550 in 2006. Total assets in 2007 increased to $5,126,072 up from $4,119,590 in 2006. While total liabilities in 2007 increased to $1,633,694 up from $1,123,900 in 2006.
Stockholders equity increased to $3,492,378 in 2007 up from $2,995,690 in 2006. Earnings per share for fiscal year 2007 was $0.63 per common share (basic) and $0.58 per common share fully diluted compared to $0.25 and $.24 per share respectively in 2006.
ABOUT THE COMPANY:
PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.
CONTACT: Jack L. McCall, EVP & COO of PD-Rx Pharmaceuticals, Inc.,